Griffin Asset Management Inc. Has $4.14 Million Holdings in Pulse Biosciences, Inc. (NASDAQ:PLSE)

Griffin Asset Management Inc. lessened its stake in Pulse Biosciences, Inc. (NASDAQ:PLSE) by 7.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 237,547 shares of the company’s stock after selling 19,902 shares during the period. Griffin Asset Management Inc. owned 0.39% of Pulse Biosciences worth $4,136,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in PLSE. Charles Schwab Investment Management Inc. boosted its stake in Pulse Biosciences by 193.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company’s stock valued at $2,598,000 after acquiring an additional 97,565 shares during the last quarter. State Street Corp lifted its stake in shares of Pulse Biosciences by 17.8% in the 3rd quarter. State Street Corp now owns 461,333 shares of the company’s stock valued at $8,092,000 after purchasing an additional 69,696 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of Pulse Biosciences in the 3rd quarter worth $588,000. Geode Capital Management LLC grew its stake in shares of Pulse Biosciences by 7.8% during the third quarter. Geode Capital Management LLC now owns 457,165 shares of the company’s stock worth $8,020,000 after purchasing an additional 33,200 shares during the period. Finally, Barclays PLC grew its stake in shares of Pulse Biosciences by 361.4% during the third quarter. Barclays PLC now owns 30,306 shares of the company’s stock worth $530,000 after purchasing an additional 23,738 shares during the period. 76.95% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded Pulse Biosciences to a “sell” rating in a report on Thursday, January 2nd.

Pulse Biosciences Stock Up 3.0 %

Shares of NASDAQ:PLSE opened at $18.66 on Tuesday. The company has a 50 day moving average price of $18.38 and a two-hundred day moving average price of $17.72. Pulse Biosciences, Inc. has a 52 week low of $6.59 and a 52 week high of $22.69.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share (EPS) for the quarter. During the same quarter in the prior year, the business earned ($0.19) EPS.

Insiders Place Their Bets

In other news, Director Robert W. Duggan purchased 55,256 shares of the business’s stock in a transaction dated Friday, December 13th. The shares were bought at an average cost of $17.18 per share, for a total transaction of $949,298.08. Following the completion of the acquisition, the director now directly owns 42,328,717 shares in the company, valued at approximately $727,207,358.06. This trade represents a 0.13 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Burke Thomas Barrett sold 50,000 shares of the company’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $17.42, for a total value of $871,000.00. Following the transaction, the chief executive officer now directly owns 63,172 shares of the company’s stock, valued at $1,100,456.24. This represents a 44.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 71.50% of the company’s stock.

Pulse Biosciences Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.